Downtime Plans Treatment & Therapy Plans
Loading Documents
- CAPEIRI EVERY 21 DAYS
- CAPEIRI BEVACIZUMAB EVERY 21 DAYS
- CAPEOX BEVACIZUMAB EVERY 14 DAYS
- CAPEOX CETUXIMAB EVERY 14 DAYS
- CAPEOX WEEKLY CETUXIMAB EVERY 21 DAYS
- CARBOPLATIN AUC 5 WEEKLY PACLITAXEL BREAST EVERY 21 DAYS
- CARBOPLATIN DOCETAXEL TRASTUZUMAB TCH EVERY 21 DAYS
- CISPLATIN GEMCITABINE TORIPALIMAB EVERY 21 DAYS
- CLL IP BENDAMUSTINE 100 RITUXIMAB 375 START ON DAY 1
- DOCETAXEL DOXORUBICIN CYCLOPHOSPHAMIDE TAC EVERY 21 DAYS
- DOCETAXEL OXALIPLATIN 5FU TFOX EVERY 21 DAYS
- DOSTARLIMAB 1000 MG MAINTENANCE EVERY 42 DAYS
- DOSTARLIMAB MONOTHERAPY EVERY 21 DAYS X 4 THEN EVERY 42 DAYS
- ETOPOSIDE D1 D5 CISPLATIN D1 D5 TESTICULAR CANCER EVERY 21 DAYS
- GEMCITABINE OXALIPLATIN RITUXIMAB EVERY 14 DAYS
- GEMCITABINE D1D8 EVERY 21 DAYS
- IP OP RSH PRO00036343 IMCGP100 203 ARM A TEBENTAFUSP
- IP OP RSH PRO00036343 IMCGP100 203 ARM B
- IP OP VAC IE EVERY 14 DAYS INTERVAL COMPRESSED
- IP OP VAC IE EVERY 21 DAYS
- IP 5FU CONCURRENT WITH RADIATION
- IP 5FU LEUCOVORIN EVERY 14 DAYS
- IP 5FU MITOMYCIN CONCURRENT WITH RADIATION
- IP ABVD
- IP AC
- IP AC DOSE DENSE
- IP AIM
- IP ALEMTUZUMAB
- IP APL INDUCTION LOW INTERMEDIATE
- IP APLASTIC ANEMIA ATG CSA
- IP APML4 FIRST CONSOLIDATION
- IP APML4 INDUCTION
- IP AUGMENTED CVAD PEGASPARGASE C VAD DRUGS PART A ARA C MTX VINC DRUGS PART B
- IP AVD BRENTUXIMAB
- IP AYA REMISSION INDUCTION CALGB 10403
- IP AZACITIDINE 5 DAYS
- IP AZACITIDINE 7 DAYS
- IP BENDAMUSTINE BORTEZOMIB PREDNISONE
- IP BEP
- IP BEVACIZUMAB 10MG KG EVERY 14 DAYS
- IP BLINATUMOMAB
- IP BORTEZOMIB EVERY 14 DAYS
- IP BORTEZOMIB DEXAMETHASONE EVERY 21 DAYS
- IP BORTEZOMIB DEXAMETHASONE EVERY 7 DAYS
- IP BORTEZOMIB DEXAMETHASONE CYCLOPHOSHAMIDE
- IP BRENTUXIMAB VEDOTIN
- IP CAGT ALLOGENEIC SCT HAPLO MEL FLU TBI WITH POST TRANSPLANT CYCLOPHOSPHAMIDE
- IP CAGT ALLOGENEIC SCT BU CY WITH TACROLIMUS and MINI METHOTREXATE GVHD PROPHYLAXIS
- IP CAGT ALLOGENEIC SCT BU FLU WITH TACROLIMUS and MINI METHOTREXATE GVHD PROPHYLAXIS
- IP CAGT ALLOGENEIC SCT CAMGRAFT
- IP CAGT ALLOGENEIC SCT CY TBI
- IP CAGT ALLOGENEIC SCT CY TBI CAM
- IP CAGT ALLOGENEIC SCT FLU MEL WITH TACROLIMUS and MINI METHOTREXATE GVHD PROPHYLAXIS
- IP CAGT ALLOGENEIC SCT FLU MEL CAM
- IP CAGT ALLOGENEIC SCT FLU MEL PTCY
- IP CAGT ALLOGENEIC SCT IV BU CY CAM
- IP CAGT ALLOGENEIC SCT IV BU FLU CAM
- IP CAGT ALLOGENEIC SCT IV BU FLU PTCY
- IP CAGT ALLOGENEIC SCT IV CLO BU CAM
- IP CAGT ALLOGENEIC SCT SAAHAPLO ATG RABBIT CY FLU TBI PTCY
- IP CAGT ALLOGENEIC SCT SAAMUD
- IP CAGT AUTOLOGOUS MOBILIZATION CYTARABINE
- IP CAGT AUTOLOGOUS MOBILIZATION HIGH DOSE CYCLOPHOSPHAMIDE
- IP CAGT AUTOLOGOUS SCT HIGH DOSE ETOPOSIDE CARBOPLATIN EINHORN PROTOCOL
- IP CAGT AUTOLOGOUS SCT HIGH DOSE ETOPOSIDE CARBOPLATIN TICE PROTOCOL
- IP CAGT AUTOLOGOUS SCT HIGH DOSE MELPHALAN
- IP CAGT AUTOLOGOUS SCT IV BEAM
- IP CAGT AUTOLOGOUS SCT IV BEAM R
- IP CAGT AUTOLOGOUS SCT IV CARMUSTINE THIOTEPA MATRIX
- IP CAGT PACLITAXEL IFOSFAMIDE TI MOBILIZATION FOR GERM CELL TUMOR
- IP CAGT R IE
- IP CARBOPLATIN AUC 6 DOCETAXEL 75 MG M2
- IP CARBOPLATIN AUC 2 GEMCITABINE EVERY 21 DAYS
- IP CARBOPLATIN AUC 5 GEMCITABINE 1000 MG M2
- IP CARBOPLATIN AUC 5 LIPOSOMAL DOXORUBICIN 30
- IP CARBOPLATIN AUC 6 PACLITAXEL 175 GYNECOLOGIC
- IP CARBOPLATIN ETOPOSIDE EVERY 21 DAYS
- IP CARBOPLATIN GEMCITABINE
- IP CARBOPLATIN NAB PACLITAXEL
- IP CARBOPLATIN PACLITAXEL DOSE DENSE
- IP CARBOPLATIN PACLITAXEL LUNG
- IP CARBOPLATIN PACLITAXEL BEVACIZUMAB
- IP CARBOPLATIN PACLITAXEL BEVACIZUMAB DOSE DENSE
- IP CARBOPLATIN PACLITAXEL W CONCURRENT THORACIC RT
- IP CARBOPLATIN PEMETREXED
- IP CARBOPLATIN PEMETREXED BEVACIZUMAB
- IP CARBOPLATIN DESENSITIZATION
- IP CARFILZOMIB INITIAL CYCLE
- IP CEOP
- IP CHOP
- IP CIA
- IP CISPLATIN DOCETAXEL EVERY 21 DAYS
- IP CISPLATIN DOCETAXEL 5FU
- IP CISPLATIN DOXORUBICIN
- IP CISPLATIN ETOPOSIDE EVERY 21 DAYS
- IP CISPLATIN ETOPOSIDE W CONCURRENT THORACIC RT EVERY 21 DAYS
- IP CISPLATIN GEMCITABINE EVERY 21 DAYS
- IP CISPLATIN IRINOTECAN EVERY 21 DAYS D1 D8
- IP CISPLATIN PACLITAXEL
- IP CISPLATIN PACLITAXEL INTRAPERITONEAL
- IP CISPLATIN PACLITAXEL BEVACIZUMAB
- IP CISPLATIN PEMETREXED
- IP CISPLATIN 60 ETOPOSIDE 100 EVERY 21 DAYS
- IP CISPLATIN W CONCURRENT RT EVERY 7 DAYS
- IP CLADRIBINE 0.09 7 DAYS
- IP CLADRIBINE 0.14 DAILY
- IP CLAG
- IP CLIA
- IP CLOFARABINE CYTARABINE
- IP CODOX A
- IP CYBORDEX
- IP CYCLOPHOSPHAMIDE FLUDARABINE LIFILEUCEL HIGH DOSE IL 2
- IP CYCLOPHOSPHAMIDE VINCRISTINE MERCAPTOPURINE CYTARABINE PEGASPARGASE
- IP CYTARABINE DAUNORUBICIN GEMTUZUMAB 7 3
- IP CYTARABINE IDARUBICIN 7 3
- IP CYTARABINE 100 DAUNORUBICIN 60 7 3
- IP DARATUMUMAB
- IP DEANGELIS METHOTREXATE VINCRISTINE LEUCOVORIN PROCARBAZINE CYCLES 1 3 5
- IP DEANGELIS WITH RITUXIMAB METHOTREXATE VINCRISTINE LEUCOVORIN CYCLES 2 AND 4
- IP DEANGELIS WITH RITUXIMAB METHOTREXATE VINCRISTINE LEUCOVORIN PROCARBAZINE CYCLES 1 3 5
- IP DECITABINE 28 DAYS
- IP DHAP
- IP DOCETAXEL
- IP DOCETAXEL 75 MG M2 EVERY 21 DAYS
- IP EP
- IP EPOCH
- IP ERIBULIN
- IP ESHAP
- IP FLAG IDA
- IP FLAG IDA CONSOLIDATION
- IP FLAT DOSE CYTARABINE
- IP FLUDARABINE CYCLOPHOSPHAMIDE RITUXIMAB
- IP FOLFIRI EVERY 14 DAYS
- IP FOLFIRI BEVACIZUMAB EVERY 14 DAYS
- IP FOLFIRINOX EVERY 14 DAYS
- IP FOLFOXIRI EVERY 14 DAYS
- IP FOLFOXIRI BEVACIZUMAB EVERY 14 DAYS
- IP FOLFOXIRI PANITUMUMAB EVERY 14 DAYS
- IP GDP
- IP GEMCITABINE CISPLATIN EVERY 21 DAYS
- IP GEMCITABINE CISPLATIN EVERY 21 DAYS LUNG
- IP GEMCITABINE CISPLATIN SPLIT DOSE
- IP GEMCITABINE DOCETAXEL
- IP GEMCITABINE 1000 EVERY 28 DAYS
- IP GEMCITABINE 1000 MG M2 EVERY 21 DAYS
- IP GEMCITABINE 800 EVERY 7 DAYS
- IP GEMCITABINE 800 MG M2 EVERY 21 DAYS
- IP GEMOX 675 80
- IP HIDAC D1 3 5
- IP HIDAC D1 3 5 IDARUBICIN
- IP HIGH DOSE METHOTREXATE LEUCOVORIN DAY 2
- IP HYPERCVAD A AND B ALTERNATING
- IP ICE
- IP IFOSFAMIDE ETOPOSIDE
- IP INOTUZUMAB OZOGAMICIN CONSOLIDATION
- IP INOTUZUMAB OZOGAMICIN INDUCTION
- IP INTRATHECAL CHEMOTHERAPY
- IP LIPOSOMAL DOXORUBICIN EVERY 14 DAYS
- IP LIPOSOMAL DOXORUBICIN EVERY 28 DAYS
- IP LIPOSOMAL DOXORUBICIN BEVACIZUMAB
- IP LIPOSOMAL IRINOTECAN LEUCOVORIN FLUOROURACIL
- IP MATRIX
- IP MEC 5 DAYS
- IP MFOLFOX6 EVERY 14 DAYS
- IP MFOLFOX6 BEVACIZUMAB EVERY 14 DAYS
- IP MINICHOP
- IP MODIFIED CYBORDEX
- IP MODIFIED FOLFIRINOX EVERY 2 WEEKS
- IP MVAC DOSE DENSE
- IP NAB PACLITAXEL GEMCITABINE
- IP NAB PACLITAXEL GEMCITABINE DOSE REDUCED EVERY 28 DAYS
- IP OBINUTUZUMAB CHLORAMBUCIL CYCLE 1 ONLY
- IP OXALIPLATIN DESENSITIZATION
- IP PACLITAXEL DOSE DENSE EVERY 21 DAYS
- IP PACLITAXEL 80 EVERY 21 DAYS
- IP PACLITAXEL 80 EVERY 28 DAYS
- IP PACLITAXEL 80 EVERY 7 DAYS
- IP PAD
- IP PEMETREXED
- IP PRALATREXATE
- IP R CEOP
- IP R CHOP
- IP R CVP
- IP R DHAP
- IP R EPOCH
- IP R ESHAP
- IP R HIGH DOSE METHOTREXATE LEUCOVORIN DAY 2
- IP R HYPERCVAD A AND B ALTERNATING
- IP R ICE
- IP R MINICHOP
- IP RESEARCH HILL CTL H 43761 CRIMSON NE
- IP RESEARCH INCA34176 357 H 56778 HILL
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM B AGE 70 OR YOUNGER UNFIT PATIENT SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM B FIT PATIENTS AGES 18 70 SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM C INTENSIFICATION SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM E AGE 70 OR YOUNGER UNFIT PATIENT SHAH
- IP RESEARCH PRO00035985 EA9181 NCT04530565 ARM E FIT PATIENTS AGES 18 70 SHAH
- IP RESEARCH PRO00038056 HMCC HM24 001 5HMC 7 3 ARM SHAH
- IP RESEARCH PRO00038056 HMCC HM24 001 5HMC FLAG IDA VENETOCLAX ARM SHAH
- IP RESEARCH PRO00038056 HMCC HM24 001 5HMC FLAG IDA ARM SHAH
- IP RITUXIMAB 375 WEEKLY
- IP RITUXIMAB 375 BORTEZOMIB CYCLE 1 ONLY
- IP ROMIDEPSIN
- IP TC
- IP TECLISTAMAB CQYV
- IP TEMOZOLOMIDE RITUXIMAB
- IP TIP GERM CELL TUMORS
- IP TOPOTECAN DAILY
- IP TOPOTECAN EVERY 21 DAYS D1 D8 D15
- IP TOPOTECAN WEEKLY
- IP TOPOTECAN BEVACIZUMAB
- IP TOPOTECAN BEVACIZUMAB EVERY 7 DAYS
- IP TRANSARTERIAL CHEMOEMBOLIZATION
- IP VAC ALTERNATING WITH IE
- IP VAD
- IP VD PACE
- IP VINCRISTINE EVERY 28 DAYS
- IP VINORELBINE EVERY 7 DAYS
- IP VIP
- IP VYXEOS CONSOLIDATION
- IP VYXEOS INDUCTION
- IP XELIRI EVERY 21 DAYS
- IP XELIRI BEVACIZUMAB EVERY 21 DAYS
- IP XELOX EVERY 21 DAYS
- IP XELOX BEVACIZUMAB EVERY 21 DAYS
- IP OP BIWEEKLY TALQUETAMAB TGVS TALVEY
- IP OP BLINATUMOMAB MRD EVERY 42 DAYS
- IP OP EMA CO
- IP OP HYPERFRACTIONATED CYCLOPHOSPHAMIDE
- IP OP PRO00037952 CABA 201 002 FOR IIM OR JIIM
- IP OP PRO00038144 CABA 201
- IP OP PRO00038933 EMN30 ARM A TEC LEN
- IP OP PRO00038933 EMN30 ARM C TEC
- IP OP RESEARCH PRO00035985 EA9181 NCT04530565 ARM C SHAH
- IP OP RESEARCH PRO00035985 EA9181 NCT04530565 ARM D SHAH
- IP OP RESEARCH PRO00037627 GANGULY P BCMA ALL01 OPEN LABEL PHASE I ARM P1
- IP OP RESEARCH PRO00037627 GANGULY P BCMA ALL01 OPEN LABEL PHASE I ARM P1.5
- IP OP RESEARCH PRO00037922 GANGULY PFIZER C1071032 OPEN LABEL ELRANATAMAB ARM A
- IP OP RESEARCH PRO00038139 IOV LUN 202 TREATMENT AND POST TREATMENT PERIOD ZHANG
- IP OP RESEARCH PRO00038239 NCT06413498 ANITOCABTAGENE AUTOLEUCEL ARM
- IP OP RESEARCH PRO00038439 AC220 168 PLAN A INDUCTION WITH 7 3 CYCLES 1 AND 2 WITH CYTARABINE DAUNORUBICIN
- IP OP RESEARCH PRO00038439 AC220 168 PLAN B INDUCTION WITH 7 3 CYCLES 1 AND 2 WITH CYTARABINE IDARUBICIN
- IP OP RESEARCH PRO00038439 AC220 168 PLAN C INDUCTION WITH 7 3 CYCLE 1 FOLLOWED BY 5 2 CYCLE 2 CYTARABINE DAUNORUBICIN
- IP OP RESEARCH PRO00038439 AC220 168 PLAN D INDUCTION WITH 7 3 CYCLE 1 FOLLOWED BY 5 2 CYCLE 2 CYTARABINE IDARUBICIN
- IP OP RESEARCH PRO00038439 AC220 168 PLAN E CONSOLIDATION
- IP OP RSH CILESTE H 47906
- IP OP RSH PRO00038180 EFSTATHIOU JANX007 SCREENING
- IP OP RSH PRO00038180 EFSTATHIOU JANX007 STEP DOSE SCHEDULE B
- IP OP RSH PRO00038180 EFSTATHIOU JANX007 STEPPED DOSE SCHEDULE A
- IP OP RSH PRO00041409 GANGULY MAJESTEC 7 ARM A
- IP OP RSH PRO00041409 GANGULY MAJESTEC 7 ARM B
- IP OP RSH PRO00041409 GANGULY MAJESTEC 7 ARM C
- IP OP RSH PRO00041409 GANGULY MAJESTEC 7 SCREENING
- IP OP RSH PRO00042030 ZHANG MK 6070 003 ARM 1 PART A AND B
- IP OP RSH PRO00042030 ZHANG MK 6070 003 ARM 2 PART A AND B
- IP OP RSH PRO00042030 ZHANG MK 6070 003 ARM 3 PART B
- IP OP TARLATAMAB DLLE
- IP OP TEBENTAFUSP TEBN
- IP OP WEEKLY TALQUETAMAB TGVS TALVEY
- LIPOSOMAL DOXORUBICIN EVERY 14 DAYS
- MFOLFOX TRASTUZUMAB EVERY 14 DAYS
- NHL IP BENDAMUSTINE 120 RITUXIMAB 375 START ON DAY 2
- NHL IP BENDAMUSTINE 90 RITUXIMAB 375 START ON DAY 1
- NHL IP BENDAMUSTINE 90 RITUXIMAB 375 START ON DAY 2
- NIVOLUMAB HYALURONIDASE FLAT DOSE EVERY 28 DAYS
- NOGAPENDEKIN ALFA INBAKICEPT PMLN ANKTIVA BCG BACILLUS CALMETTE GUERIN EVERY 7 DAYS CYCLES INDUCTION
- NOGAPENDEKIN ALFA INBAKICEPT PMLN ANKTIVA BCG BACILLUS CALMETTE GUERIN MAINTENANCE
- OP 5FU MITOMYCIN CONCURRENT WITH RADIATION
- OP ABVD
- OP ADO TRASTUZUMAB EMTANSINE EVERY 21 DAYS
- OP AIM
- OP ALEMTUZUMAB
- OP AMIVANTAMAB VMJW
- OP AMIVANTAMAB CARBOPLATIN AUC 5 PEMETREXED CYCLES 1 TO 4
- OP AMIVANTAMAB PEMETREXED MAINTENANCE
- OP APML4 SECOND CONSOLIDATION
- OP ARSENIC TRIOXIDE CONSOLIDATION
- OP ARSENIC TRIOXIDE INDUCTION
- OP ARSENIC TRIOXIDE MAINTENANCE EVERY 28 DAYS
- OP ATEZOLIZUMAB EVERY 21 DAYS
- OP ATEZOLIZUMAB BEVACIZUMAB EVERY 21 DAYS
- OP ATEZOLIZUMAB 1680 MG EVERY 28 DAYS
- OP AVD BRENTUXIMAB
- OP AVELUMAB EVERY 14 DAYS
- OP AYA COURSE 1 REMISSION INDUCTION
- OP AYA COURSE 1A EXTENDED REMISSION INDUCTION
- OP AYA COURSE 2 REMISSION CONSOLIDATION
- OP AYA COURSE 3 INTERIM MAINTENANCE
- OP AYA COURSE 4 DELAYED INTENSIFICATION
- OP AYA COURSE 5 MAINTENANCE THERAPY
- OP AZACITIDINE 5 DAYS
- OP AZACITIDINE 7 DAYS
- OP BCG VIA NEPHROSTOMY TUBE
- OP BELANTAMAB MAFODOTIN BLMF EVERY 21 DAYS
- OP BENDAMUSTINE OBINUTUZUMAB NHL EVERY 28 DAYS
- OP BENDAMUSTINE RITUXIMAB DAY 1 START CLL
- OP BEP
- OP BEVACIZUMAB EVERY 14 DAYS
- OP BEVACIZUMAB EVERY 21 DAYS
- OP BLANK CHEMOTHERAPY PLAN EVERY 21 DAYS
- OP BORTEZOMIB EVERY 21 DAYS
- OP BORTEZOMIB EVERY 7 DAYS
- OP BORTEZOMIB MAINTENANCE EVERY 14 DAYS
- OP BRENTUXIMAB VEDOTIN EVERY 21 DAYS
- OP CABAZITAXEL EVERY 21 DAYS
- OP CAGT AUTOLOGOUS MOBILIZATION HIGH DOSE CYCLOPHOSPHAMIDE
- OP CAGT AUTOLOGOUS SCT IV RITUXIMAB BEAM R
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE TISAGENLECLEUCEL ACUTE LYMPHOCYTIC LEUKEMIA ALL
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE TISAGENLECLEUCEL DIFFUSE LARGE B CELL LYMPHOMA DLBCL
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE LYMPHODEPLETION MAGENTA
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE LYMPHODEPLETION MB105 201
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE LYMPHODEPLETION RELY 30
- OP CAGT CYCLOPHOSPHAMIDE FLUDARABINE AXICABTAGENE CILOLEUCEL DIFFUSE LARGE B CELL LYMPHOMA DLBCL
- OP CAGT R IE
- OP CAP
- OP CAPEOX EVERY 21 DAYS
- OP CARBOPLATIN AUC 4 GEMCITABINE BEVACIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 5 PACLITAXEL DOSTARLIMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 5 WEEKLY PACLITAXEL PEMBROLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 NAB PACLITAXEL WEEKLY PEMBROLIZUMAB X 4 CYCLES FOLLOWED BY PEMBROLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 NAB PACLITAXEL D1D8D15 EVERY 21 DAYS
- OP CARBOPLATIN AUC 2 PACLITAXEL WITH CONCURRENT THORACIC RT EVERY 7 DAYS
- OP CARBOPLATIN AUC 2 WITH CONCURRENT RADIATION EVERY 7 DAYS
- OP CARBOPLATIN AUC 4 CABAZITAXEL EVERY 21 DAYS
- OP CARBOPLATIN AUC 5 ETOPOSIDE ATEZOLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 5 FLUOROURACIL CADD PEMBROLIZUMAB HEAD AND NECK EVERY 21 DAYS
- OP CARBOPLATIN AUC 5 GEMCITABINE NIVOLUMAB LUNG CANCER EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PACLITAXEL BEVACIZUMAB ATEZOLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PACLITAXEL BEVACIZUMAB GYNECOLOGIC EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PACLITAXEL NIVOLUMAB LUNG CANCER EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PACLITAXEL GYNECOLOGIC EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PACLITAXEL LUNG EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PEMETREXED BEVACIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 WEEKLY PACLITAXEL BEVACIZUMAB DOSE DENSE EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 WEEKLY PACLITAXEL DOSE DENSE EVERY 21 DAYS
- OP CARBOPLATIN AUC 6 PACLITAXEL PEMBROLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN AUC 5 PACLITAXEL PEMBROLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN DOCETAXEL
- OP CARBOPLATIN ETOPOSIDE EVERY 21 DAYS
- OP CARBOPLATIN ETOPOSIDE W ACC HYPERFX RADIATION
- OP CARBOPLATIN GEMCITABINE D1D8 EVERY 21 DAYS
- OP CARBOPLATIN LIPOSOMAL DOXORUBICIN
- OP CARBOPLATIN PEMETREXED
- OP CARBOPLATIN PEMETREXED PEMBROLIZUMAB EVERY 21 DAYS
- OP CARBOPLATIN WEEKLY CETUXIMAB EVERY 21 DAYS
- OP CARBOPLATIN D1D8 GEMCITABINE D1D8 EVERY 21 DAYS
- OP CARFILZOMIB INITIAL AND MAINTENANCE
- OP CARFILZOMIB INITIAL CYCLE
- OP CARFILZOMIB MAINTENANCE
- OP CARFILZOMIB WEEKLY
- OP CARMUSTINE BEVACIZUMAB EVERY 42 DAYS
- OP CEMIPLIMAB EVERY 21 DAYS
- OP CETUXIMAB EVERY 14 DAYS
- OP CETUXIMAB EVERY 7 DAYS
- OP CETUXIMAB PEMBROLIZUMAB EVERY 42 DAYS
- OP CHOEP EVERY 21 DAYS
- OP CHOP
- OP CISPLATIN EVERY 21 DAYS
- OP CISPLATIN DOCETAXEL EVERY 21 DAYS
- OP CISPLATIN DOCETAXEL 5FU
- OP CISPLATIN DOXORUBICIN EVERY 21 DAYS
- OP CISPLATIN ETOPOSIDE EVERY 21 DAYS
- OP CISPLATIN ETOPOSIDE WITH CONCURRENT RADIATION SCLC NECC EVERY 21 DAYS
- OP CISPLATIN ETOPOSIDE WITH CONCURRENT RADIATION THORACIC NSCLC EVERY 28 DAYS
- OP CISPLATIN GEMCITABINE EVERY 21 DAYS
- OP CISPLATIN GEMCITABINE PEMBROLIZUMAB NSCLC EVERY 21 DAYS
- OP CISPLATIN IRINOTECAN EVERY 21 DAYS D1 D8 D15
- OP CISPLATIN PACLITAXEL EVERY 21 DAYS
- OP CISPLATIN PACLITAXEL BEVACIZUMAB EVERY 21 DAYS
- OP CISPLATIN PEMETREXED
- OP CISPLATIN PEMETREXED NIVOLUMAB EVERY 21 DAYS
- OP CISPLATIN PEMETREXED PEMBROLIZUMAB NSCLC EVERY 21 DAYS
- OP CISPLATIN PEMETREXED WITH CONCURRENT RADIATION EVERY 21 DAYS
- OP CISPLATIN VINORELBINE EVERY 21 DAYS
- OP CISPLATIN D1D8 GEMCITABINE D1D8 EVERY 28 DAYS
- OP CISPLATIN W CONCURRENT RT EVERY 7 DAYS
- OP CISPLATIN W CONCURRENT RT EVERY 21 DAYS
- OP CISPLATIN SPLIT DOSE IRINOTECAN EVERY 21 DAYS
- OP CLADRIBINE DAILY
- OP CLADRIBINE WEEKLY
- OP CLOFARABINE CYTARABINE
- OP CMF
- OP CVP
- OP CYBORDEX
- OP CYCLOPHOSPHAMIDE VINCRISTINE MERCAPTOPURINE CYTARABINE PEGASPARGASE
- OP DARATUMUMAB
- OP DARATUMUMAB BORTEZOMIB DEXAMETHASONE
- OP DARATUMUMAB HYALURONIDASE DARZALEX FASPRO
- OP DARATUMUMAB HYALURONIDASE FIHJ BORTEZOMIB DEXAMETHASONE GRIFFIN TRIAL
- OP DARATUMUMAB HYALURONIDASE FIHJ CARFILZOMIB DEXAMETHASONE CANDOR TRIAL EVERY 28 DAYS
- OP DARATUMUMAB HYALURONIDASE FIHJ WEEKLY BORTEZOMIB LENALIDOMIDE DEXAMETHASONE PERSEUS
- OP DARZALEX FASPRO CYBORDEX ANDROMEDA PROTOCOL
- OP DARZALEX FASPRO CYBORDEX LYRA PROTOCOL
- OP DATOPOTAMAB DERUXTECAN EVERY 21 DAYS
- OP DECITABINE 28 DAYS
- OP DOCETAXEL EVERY 21 DAYS
- OP DOXORUBICIN CYCLOPHOSPHAMIDE EVERY 21 DAYS
- OP DOXORUBICIN CYCLOPHOSPHAMIDE PEMBROLIZUMAB EVERY 21 DAYS
- OP DOXORUBICIN CYCLOPHOSPHAMIDE DOSE DENSE EVERY 14 DAYS
- OP DOXORUBICIN 75 MG M2 BOLUS IFOSFAMIDE 10 G M2 OVER 4 DAYS MESNA CIV
- OP DOXORUBICIN 75 MG M2 BOLUS IFOSFAMIDE 10 G M2 OVER 5 DAYS MESNA BOLUS
- OP DOXORUBICIN 75 MG M2 CIV IFOSFAMIDE 10 G M2 OVER 5 DAYS MESNA BOLUS
- OP DOXORUBICIN TRABECTEDIN INDUCTION
- OP DURVALUMAB 10 MG KG EVERY 14 DAYS
- OP DURVALUMAB 1500 MG EVERY 28 DAYS
- OP DURVALUMAB GEMCITABINE CISPLATIN X 8 CYCLES EVERY 21 DAYS THEN DURVALUMAB MAINTENANCE EVERY 28 DAYS CHOLANGIOCARCINOMA
- OP DVD LOW DOSE
- OP DVD R
- OP ENFORTUMAB VEDOTIN EVERY 28 DAYS
- OP ENFORTUMAB VEDOTIN PEMBROLIZUMAB EVERY 21 DAYS
- OP EPIRUBICIN CYCLOPHOSPHAMIDE EVERY 21 DAYS
- OP ERIBULIN D1D8 EVERY 21 DAYS
- OP FAC EVERY 21 DAYS
- OP FAM TRASTUZUMAB DERUXTECAN EVERY 21 DAYS
- OP FLA
- OP FLOT EVERY 14 DAYS
- OP FLUDARABINE CYCLOPHOSPHAMIDE RITUXIMAB
- OP FLUOROURACIL WITH CONCURRENT RADIATION EVERY 7 DAYS
- OP FOLFIRI EVERY 14 DAYS
- OP FOLFIRI BEVACIZUMAB EVERY 14 DAYS
- OP FOLFIRI CETUXIMAB EVERY 14 DAYS
- OP FOLFIRI PANITUMUMAB EVERY 14 DAYS
- OP FOLFIRI RAMUCIRUMAB EVERY 14 DAYS
- OP FOLFOX WITH RADIATION ESOPHAGEAL CANCER EVERY 14 DAYS
- OP GDP
- OP GEMCITABINE EVERY 28 DAYS
- OP GEMCITABINE CISPLATIN GALLBLADDER
- OP GEMCITABINE DOCETAXEL
- OP GEMCITABINE VINORELBINE DOXORUBICIN LIPOSOMAL
- OP GEMOX 1000 100 EVERY 14 DAYS
- OP IFOSFAMIDE XRT
- OP IMETELSTAT RYTELO
- OP INOTUZUMAB OZOGAMICIN CONSOLIDATION
- OP INOTUZUMAB OZOGAMICIN INDUCTION
- OP INTRATHECAL CHEMOTHERAPY
- OP INTRAVESICAL GEMCITABINE DOCETAXEL PLAN MONTHLY MAINTENANCE FOR 1 YEAR
- OP IPILIMUMAB NIVOLUMAB EVERY 21 DAYS
- OP IPILIMUMAB NIVOLUMAB NSCLC EVERY 42 DAYS
- OP IRINOTECAN CETUXIMAB EVERY 14 DAYS
- OP IROX
- OP ISATUXIMAB CARFILZOMIB DEXAMETHASONE IKEMA
- OP IXABEPILONE
- OP KEYNOTE A18
- OP LIPOSOMAL DOXORUBICIN EVERY 28 DAYS
- OP LIPOSOMAL DOXORUBICIN BEVACIZUMAB EVERY 28 DAYS
- OP LIPOSOMAL IRINOTECAN FLUOROURACIL EVERY 14 DAYS
- OP LONCASTUXIMAB TESIRINE LPYL INITIAL AND MAINTENANCE DOSE
- OP LOW DOSE CYTARABINE 10 DAYS
- OP LURBINECTEDIN EVERY 21 DAYS
- OP MARGETUXIMAB ERIBULIN EVERY 21 DAYS
- OP MARGETUXIMAB GEMCITABINE EVERY 21 DAYS
- OP MARGETUXIMAB VINORELBINE EVERY 21 DAYS
- OP MFOLFOX6 EVERY 14 DAYS
- OP MFOLFOX6 BEVACIZUMAB EVERY 14 DAYS
- OP MFOLFOX6 CETUXIMAB EVERY 14 DAYS
- OP MFOLFOX6 NIVOLUMAB EVERY 14 DAYS
- OP MFOLFOX6 PANITUMUMAB EVERY 14 DAYS
- OP MINICHOP
- OP MIRVETUXIMAB SORAVTANSINE GYNX EVERY 21 DAYS
- OP MITOMYCIN GEL FOR PYELOCALICEAL INSTILLATION INITIATION EVERY 7 DAYS
- OP MITOXANTRONE PREDNISONE
- OP MODIFIED CYBORDEX
- OP MODIFIED FOLFIRINOX EVERY 2 WEEKS
- OP MOGAMULIZUMAB EVERY 28 DAYS
- OP MVAC DOSE DENSE
- OP NAB PACLITAXEL EVERY 21 DAYS
- OP NAB PACLITAXEL D1D8D15 GEMCITABINE D1D8D15 EVERY 28 DAYS
- OP NADOFARAGENE FIRADENOVEC ADSTILADRIN
- OP NIVOLUMAB 240 MG FLAT DOSE EVERY 14 DAYS
- OP NIVOLUMAB 3 MG KG EVERY 14 DAYS
- OP NIVOLUMAB AND RELATLIMAB EVERY 28 DAYS
- OP OBINUTUZUMAB EVERY 28 DAYS
- OP PACLITAXEL CARBOPLATIN AUC 2 EVERY 28 DAYS
- OP PACLITAXEL WEEKLY EVERY 7 DAYS
- OP PACLITAXEL DOSE DENSE EVERY 14 DAYS
- OP PANITUMUMAB EVERY 14 DAYS
- OP PEMBROLIZUMAB 200 MG EVERY 21 DAYS
- OP PEMBROLIZUMAB 400 MG EVERY 42 DAYS
- OP PEMETREXED EVERY 21 DAYS
- OP POLATUZUMAB BENDAMUSTINE RITUXIMAB NHL EVERY 21 DAYS
- OP POMP
- OP PRALATREXATE
- OP PRO00037422 LU22 SCREENING
- OP PRO00037422 LU22 TREATMENT
- OP PRO00038124 ARM 1 DATO DXD DURVALUMAB NEOADJUVANT SETTING EXPERIMENTAL
- OP PRO00038124 ARM 1 DURVALUMAB 1120 MG CHEMOTHERAPY ADJUVANT SETTING EXPERIMENTAL
- OP PRO00038124 ARM 1 DURVALUMAB 1120 MG ADJUVANT SETTING EXPERIMENTAL
- OP PRO00038124 ARM 2 OP AC PEMBROLIZUMAB NEOADJUVANT SETTING CONTROL
- OP PRO00038124 ARM 2 OP CARBOPLATIN AUC 5 WEEKLY PACLITAXEL PEMBROLIZUMAB NEOADJUVANT SETTING CONTROL
- OP PRO00038124 ARM 2 PEMBROLIZUMAB CHEMOTHERPAY ADJUVANT SETTING CONTROL
- OP PRO00038124 ARM 2 PEMBROLIZUMAB ADJUVANT SETTING CONTROL
- OP PRO00038124 SCREENING
- OP PRO00038327 SPI BEL 301 GROUP 2B PRALATREXATE 30 MG M2 COP
- OP PRO00038327 SPI BEL 301 GROUP 1A BEL CHOP BELINOSTAT 600 MG M2
- OP PRO00038327 SPI BEL 301 GROUP 1B BEL CHOP BELINOSTAT 1000 MG M2
- OP PRO00038327 SPI BEL 301 GROUP 2A PRALATREXATE 20 MG M2 COP
- OP PRO00038327 SPI BEL 301 GROUP 3 CONTROL ARM CHOP
- OP PRO00038327 SPI BEL 301 SCREENING
- OP PRO00038456 YTB323
- OP PRO00038487 PRISM 1 PLAN 3 QUEMLICLUSTAT PLACEBO ONLY CYCLES 13 24
- OP PRO00038487 PRISM 1 SCREENING
- OP PRO00038487 PRISM 1 PLAN 1 ALL ARMS QUEMLICLUSTAT PLACEBO NP GEM CYCLES 1 TO 12
- OP PRO00038487 PRISM 1 PLAN 2 NP GEM CYCLES 13 24
- OP PRO00038634 WO44263 BIOMARKER SCREENING
- OP PRO00038634 WO44263 INDUCTION SCREENING
- OP PRO00038634 WO44263 INDUCTION THERAPY PLAN A
- OP PRO00038634 WO44263 INDUCTION THERAPY PLAN B
- OP PRO00038634 WO44263 INDUCTION THERAPY PLAN C
- OP PRO00038634 WO44263 MAINTENANCE SCREENING
- OP PRO00038634 WO44263 MAINTENANCE THERAPY PLAN D
- OP PRO00038933 EMN30 ARM B LEN
- OP PRO00038933 EMN30 SCREENING
- OP PRO00040430 SMT112 3007 SCREENING ZHANG
- OP PRO00040430 SMT112 3007 ZHANG
- OP PROCARBAZINE LOMUSTINE VINCRISTINE
- OP R CEOP
- OP R CHOP
- OP R CVP
- OP R EPOCH
- OP R ICE
- OP R MINICHOP
- OP RAMUCIRUMAB EVERY 14 DAYS
- OP RAMUCIRUMAB DOCETAXEL EVERY 21 DAYS
- OP RAMUCIRUMAB PACLITAXEL EVERY 28 DAYS
- OP RESEARCH CTL BESTA H 46862
- OP RESEARCH CTL H 43516 CARMEN PROCURMENT
- OP RESEARCH H 43405 VISTA INFUSION
- OP RESEARCH H 43405 VISTA PROCUREMENT ORDERS
- OP RESEARCH H 44843 TETRAVI STUDY
- OP RESEARCH H 47739 BAT IT FOLLOW UP
- OP RESEARCH H47561 MSC COVID 19
- OP RESEARCH INCA34176 357 H 56778 ELIGIBILITY SCREENING AND CONSENT HILL
- OP RESEARCH INCA34176 357 H 56778 HILL
- OP RESEARCH PRO00021286 KAMAT NRG GY009 ARM 2
- OP RESEARCH PRO00026229 ABDELRAHIM NAPOLI 3 ARM 1
- OP RESEARCH PRO00028925 FULVESTRANT ABEMACICLIB WITH FULVESTRANT RUN IN CHANG
- OP RESEARCH PRO00028925 FULVESTRANT ABEMACICLIB WITHOUT FULVESTRANT RUN IN CHANG
- OP RESEARCH PRO00029685 A011801 JAIN
- OP RESEARCH PRO00030489 HMCC BR22 001 BASELINE ASSESSMENTS NIRAVATH
- OP RESEARCH PRO00030489 HMCC BR22 001 NIRAVATH
- OP RESEARCH PRO00030489 HMCC BR22 001 SCREENING ASSESSMENTS NIRAVATH
- OP RESEARCH PRO00031037 NCT04513717 ARM 1 HAQUE
- OP RESEARCH PRO00031037 NCT04513717 ARM 2 HAQUE
- OP RESEARCH PRO00031037 NCT04513717 ARM 3 HAQUE
- OP RESEARCH PRO00031037 NCT04513717 ARM 4 HAQUE
- OP RESEARCH PRO00032239 ML43352 ABDELRAHIM
- OP RESEARCH PRO00035654 NCT04071457 GANGULY ARM 1 STEP 2
- OP RESEARCH PRO00035654 NCT04071457 GANGULY ARM 2 STEP 2
- OP RESEARCH PRO00035654 NCT04071457 GANGULY PRE REGISTRATION STEP 2
- OP RESEARCH PRO00035985 EA9181 NCT04530565 MAINTENANCE SHAH
- OP RESEARCH PRO00035985 EA9181 NCT04530565 PRIOR TO ALLOGENIC HCT
- OP RESEARCH PRO00035985 EA9181 NCT04530565 STEP 0 PRE REGISTRATION SHAH
- OP RESEARCH PRO00035985 EA9181 NCT04530565 STEP 1 REGISTRATION PRE INDUCTION ARM A STEP 2 RANDOMIZATION SHAH
- OP RESEARCH PRO00035985 EA9181 NCT04530565 STEP 3 PRE REGISTRATION SHAH
- OP RESEARCH PRO00036193 ARM A MMY3002 GANGULY
- OP RESEARCH PRO00036193 ARM B MMY3002 GANGULY
- OP RESEARCH PRO00036193 ARM C MMY3002 GANGULY
- OP RESEARCH PRO00036218 BAYER 21516 EFSTATHIOU
- OP RESEARCH PRO00036449 RAMSHESH NRG BR007 ENDOCRINE THERAPY RT PHASE III ARM 1
- OP RESEARCH PRO00036449 RAMSHESH NRG BR007 ENDOCRINE THERAPY ONLY PHASE III ARM 2
- OP RESEARCH PRO00036449 RAMSHESH NRG BR007 PHASE III SCREENING
- OP RESEARCH PRO00036844 EFSTATHIOU AZD5305 WITH ABIRATERONE ACETATE OPEN LABEL PHASE I IIA PETRANHA ARM 2
- OP RESEARCH PRO00036844 EFSTATHIOU AZD5305 WITH DAROLUTAMIDE OPEN LABEL PHASE I IIA PETRANHA ARM 3
- OP RESEARCH PRO00036844 EFSTATHIOU AZD5305 WITH ENZALUTAMIDE OPEN LABEL PHASE I IIA PETRANHA ARM 1
- OP RESEARCH PRO00036844 EFSTATHIOU AZD5305 WITH HORMONAL AGENTS OPEN LABEL PHASE I IIA PETRANHA SCREENING
- OP RESEARCH PRO00036985 NCT05132504 POST SURGERY ESNAOLA
- OP RESEARCH PRO00036985 NCT05132504 PRE SURGERY ESNAOLA
- OP RESEARCH PRO00036985 NCT05132504 SCREEING ESNAOLA
- OP RESEARCH PRO00037014 SHAH BMS CA055 026 AZACITIDINE RANDOMIZED SCREENING
- OP RESEARCH PRO00037679 ZHANG EA5182 FOR PATIENTS WITH METASTATIC EGFR MUTANT NON SMALL CELL LUNG CANCER NSCLC RANDOMIZED SCREENING
- OP RESEARCH PRO00037679 ZHANG EA5182 OSIMERTINIB AZD9291 FOR PATIENTS WITH METASTATIC EGFR MUTANT NON SMALL CELL LUNG CANCER NSCLC RANDOMIZED ARM A
- OP RESEARCH PRO00037679 ZHANG EA5182 OSIMERTINIB AZD9291 WITH BEVACIZUMAB FOR PATIENTS WITH METASTATIC EGFR MUTANT NON SMALL CELL LUNG CANCER NSCLC RANDOMIZED ARM B
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 1B Q2W EVERY 2 WEEKS
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 1B Q4W EVERY 4 WEEKS
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 1C
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 2A Q2W EVERY 2 WEEKS
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 2A Q4W EVERY 4 WEEKS
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 2B Q2W EVERY 2 WEEKS
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 PART 2B Q4W EVERY 4 WEEKS
- OP RESEARCH PRO00037722 ABDELRAHIM CA052002 PHASE1 2 SCREENING
- OP RESEARCH PRO00037762 HMCC HM22 001 ATRA ARM 1
- OP RESEARCH PRO00037762 HMCC HM22 001 ATRA SCREENING BASELINE
- OP RESEARCH PRO00037808 D361DC00001 SUN ARM A
- OP RESEARCH PRO00037808 D361DC00001 SUN ARM B
- OP RESEARCH PRO00037808 D361DC00001 SUN SCREENING
- OP RESEARCH PRO00037831 ML44719 ABDELRAHIM ARM A
- OP RESEARCH PRO00037831 ML44719 ABDELRAHIM ARM B
- OP RESEARCH PRO00037831 ML44719 ABDELRAHIM SCREENING
- OP RESEARCH PRO00037834 IDE196 002 IND 143026 MAQSOOD PHASE 2A ARM 1
- OP RESEARCH PRO00037834 IDE196 002 IND 143026 MAQSOOD PHASE 2A ARM 2
- OP RESEARCH PRO00037834 IDE196 002 IND 143026 MAQSOOD PHASE 2A CHEMOTHERAPY ARM 3 COMPARATOR ARM
- OP RESEARCH PRO00037834 IDE196 002 IND 143026 MAQSOOD PHASE 2B AND 3 CHEMOTHERAPY ARM 2 COMPARATOR ARM
- OP RESEARCH PRO00037834 IDE196 002 IND 143026 MAQSOOD SCREENING
- OP RESEARCH PRO00037866 DB 1303 O 3002 NIRAVATH ARM 1
- OP RESEARCH PRO00037866 DB 1303 O 3002 NIRAVATH ARM 2 NAB PACLITAXEL
- OP RESEARCH PRO00037866 DB 1303 O 3002 NIRAVATH ARM 2 PACLITAXEL
- OP RESEARCH PRO00037866 DB 1303 O 3002 NIRAVATH SCREENING
- OP RESEARCH PRO00037870 SATKUNASIVAM ADJUVANT V940 MRNA 4157 RANDOMIZED DOUBLE BLIND PHASE 2
- OP RESEARCH PRO00037922 GANGULY PFIZER C1071032 ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD ARM B
- OP RESEARCH PRO00037922 GANGULY PFIZER C1071032 MAGNETISMM 32 KD ARM B
- OP RESEARCH PRO00037922 GANGULY PFIZER C1071032 OPEN LABEL SCREENING
- OP RESEARCH PRO00037933 MERCK MK 2870 005 GOG 3095 ARM 1
- OP RESEARCH PRO00037933 MERCK MK 2870 005 GOG 3095 ARM 2 DOXORUBICIN
- OP RESEARCH PRO00037933 MERCK MK 2870 005 GOG 3095 ARM 2 PACLITAXEL
- OP RESEARCH PRO00037983 NCT05899608 SCREENING ZHANG
- OP RESEARCH PRO00037983 NCT05899608 WITH CARBOPLATIN AUC 6 ABRAXANE ZHANG FOR SQUAMOUS HISTOLOGY
- OP RESEARCH PRO00037983 NCT05899608 WITH CARBOPLATIN AUC 6 PACLITAXEL ZHANG FOR SQUAMOUS HISTOLOGY
- OP RESEARCH PRO00037983 NCT05899608 WITH CARBOPLATIN AUC 5 PEMETREXED FOR NON SQUAMOUS HISTOLOGY
- OP RESEARCH PRO00037985 ZHANG J3M MC JZQB BASELINE SCREENING
- OP RESEARCH PRO00037985 ZHANG J3M MC JZQB NON SMALL CELL LUNG ARM B
- OP RESEARCH PRO00037985 ZHANG J3M MC JZQB PRE SCREENING
- OP RESEARCH PRO00038056 HMCC HM24 001 5HMC AZACITIDINE ARM SHAH
- OP RESEARCH PRO00038056 HMCC HM24 001 5HMC DECITABINE ARM SHAH
- OP RESEARCH PRO00038056 HMCC HM24 001 5HMC SCREENING and BASELINE SHAH
- OP RESEARCH PRO00038139 IOV LUN 202 PRE TREATMENT PERIOD TUMOR HARVEST BASELINE ZHANG
- OP RESEARCH PRO00038139 IOV LUN 202 SCREENING AND ENROLLMENT PERIOD PERIOD ZHANG
- OP RESEARCH PRO00038188 NCT06208150 ARM A
- OP RESEARCH PRO00038188 NCT06208150 ARM B
- OP RESEARCH PRO00038188 NCT06208150 ARM C EPD
- OP RESEARCH PRO00038188 NCT06208150 ARM C PVD
- OP RESEARCH PRO00038188 NCT06208150 SCREENING
- OP RESEARCH PRO00038209 A062102 GANGULY IBERDOMIDE
- OP RESEARCH PRO00038209 A062102 GANGULY SCREENING
- OP RESEARCH PRO00038239 NCT06413498 BRIDGE THERAPY MANDATORY PROCEDURES TO BE PERFORMED ON D1 OF C1
- OP RESEARCH PRO00038239 NCT06413498 DPD
- OP RESEARCH PRO00038239 NCT06413498 KD
- OP RESEARCH PRO00038239 NCT06413498 KDD
- OP RESEARCH PRO00038239 NCT06413498 LEUKAPHERESIS
- OP RESEARCH PRO00038239 NCT06413498 SCREENING AND RE SCREENING
- OP RESEARCH PRO00038278 DURVALUMAB BEVACIZUMAB TARE PROTOCOL
- OP RESEARCH PRO00038278 DURVALUMAB BEVACIZUMAB SCREENING BASELINE
- OP RESEARCH PRO00038285 NALIRIFOX BASELINE DAYS 7 TO 1
- OP RESEARCH PRO00038285 NALIRIFOX PROTOCOL
- OP RESEARCH PRO00038285 NALIRIFOX SCREENING DAYS 28 TO 7
- OP RESEARCH PRO00038299 NIRAVATH BEAMICON BCGC 1 COHORT A
- OP RESEARCH PRO00038299 NIRAVATH BEAMICON BCGC 1 COHORT B
- OP RESEARCH PRO00038299 NIRAVATH BEAMICON BCGC 1 COHORT C
- OP RESEARCH PRO00038299 NIRAVATH BEAMICON BCGC 1 SCREENING
- OP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD DARATUMUMAB FOR NEW AL AMYLOIDOSIS MAINTENANCE
- OP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD FOR NEW AL AMYLOIDOSIS CONSOLIDATION ARM 1
- OP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD FOR NEW AL AMYLOIDOSIS INDUCTION
- OP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD REGISTRATION PRIOR TO STEP 1
- OP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD REGISTRATION PRIOR TO STEP 2
- OP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD REGISTRATION PRIOR TO STEP 3
- OP RESEARCH PRO00038342 ALE1001 SHAH PHASE 2
- OP RESEARCH PRO00038342 ALE1001 SHAH SCREENING PHASE 2
- OP RESEARCH PRO00038369 HMCC GI24 001 ARM 1
- OP RESEARCH PRO00038369 HMCC GI24 001 ARM 2
- OP RESEARCH PRO00038369 HMCC GI24 001 SCREENING BASELINE
- OP RESEARCH PRO00038439 AC220 168 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- OP RESEARCH PRO00038439 AC220 168 ASSESSMENTS LABS PROCEDURES FOR LONG TERM FOLLOW UP
- OP RESEARCH PRO00038439 AC220 168 PLAN F MAINTENANCE
- OP RESEARCH PRO00038439 AC220 168 SCREENING BASELINE
- OP RESEARCH PRO00038457 ABLE 22 SATKUNASIVAM OPTIONAL TREATMENT PERIOD FROM MONTH 12 UP TO 24
- OP RESEARCH PRO00038457 ABLE 22 SATKUNASIVAM PLANNED TREATMENT PERIOD OF ALL SUBJECTS UP TO MONTH 12
- OP RESEARCH PRO00038502 GOG 3097 RAMP 301 KAMAT ARM 1
- OP RESEARCH PRO00038502 GOG 3097 RAMP 301 KAMAT ARM 2 LIPOSOMAL DOXORUBICIN
- OP RESEARCH PRO00038502 GOG 3097 RAMP 301 KAMAT ARM 2 PACLITAXEL
- OP RESEARCH PRO00038509 C2321014 ARM A EFSTATHIOU
- OP RESEARCH PRO00038509 C2321014 ARM B DOCETAXEL EFSTATHIOU
- OP RESEARCH PRO00038509 C2321014 ARM B ENZALUTAMIDE EFSTATHIOU
- OP RESEARCH PRO00038509 C2321014 SCREENING EFSTATHIOU
- OP RESEARCH PRO00039131 NEO ADJUVANT ARM A KIM
- OP RESEARCH PRO00039131 NEO ADJUVANT ARM B KIM
- OP RESEARCH PRO00039131 NEO ADJUVANT ARM C KIM
- OP RESEARCH PRO00039131 NEO ADJUVANT ARM D KIM
- OP RESEARCH PRO00039131 NEO ADJUVANT ARM E KIM
- OP RESEARCH PRO00039131 NEO ADJUVANT ARM F KIM
- OP RESEARCH PRO00039131 V940 009 ADJUVANT INELIGIBLE FOR RANDOMIZATION KIM
- OP RESEARCH PRO00039131 V940 009 ADJUVANT KIM
- OP RESEARCH PRO00039131 V940 009 NEO ADJUVANT SCREENING KIM
- OP RESEARCH PRO00039131 V940 009 PRE RANDOMIZATION KIM
- OP RESEARCH PRO00039188 ZHANG D516NC00001 PHASE III OPEN LABEL RANDOMIZED STUDY OF OSIMERTINIB ARM 2 VERSION 2.0
- OP RESEARCH PRO00039188 ZHANG D516NC00001 PHASE III OPEN LABEL RANDOMIZED STUDY OF OSIMERTINIB WITH DERUXTECAN ARM 1 VERSION 2.0
- OP RESEARCH PRO00039188 ZHANG D516NC00001 PHASE III OPEN LABEL RANDOMIZED STUDY OF OSIMERTINIB WITH OR WITHOUT DERUXTECAN SCREENING
- OP RESEARCH PRO00039425 PINGALI MK2140 010 RANDOMIZED PHASE 3 PLAN A ARM 1
- OP RESEARCH PRO00039425 PINGALI MK2140 010 RANDOMIZED PHASE 3 PLAN B ARM 2
- OP RESEARCH PRO00039425 PINGALI MK2140 010 RANDOMIZED PHASE 3 SCREENING AND RESCREENING OPTIONAL
- OP RESEARCH PRO00039680 GOG 3115 ABBVIE M25 231 KILOWSKI
- OP RESEARCH PRO00039815 HMCC GI25 001 ARM PLAN A
- OP RESEARCH PRO00039815 HMCC GI25 001 ARM PLAN B
- OP RESEARCH PRO00039815 HMCC GI25 001 SCREENING BASELINE
- OP RESEARCH PRO00039931 ABDELRAHIM 8951 CL 0305 PHASE III DOUBLE BLIND RANDOMIZED STUDY OF ZOLBETUXIMAB WITH PEMBROLIZUMAB AND CAPEOX ARM B
- OP RESEARCH PRO00039931 ABDELRAHIM 8951 CL 0305 PHASE III DOUBLE BLIND RANDOMIZED STUDY OF ZOLBETUXIMAB WITH PEMBROLIZUMAB AND CHEMO CAPOX OR MFOLFOX6 SCREENING
- OP RESEARCH PRO00039931 ABDELRAHIM 8951 CL 0305 PHASE III DOUBLE BLIND RANDOMIZED STUDY OF ZOLBETUXIMAB WITH PEMBROLIZUMAB AND MFOLFOX6 ARM A
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 PLAN A INDUCTION WITH CARBOPLATIN AUC 5 ZHANG
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 PLAN A INDUCTION WITH CISPLATIN ZHANG
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 PLAN B INDUCTION WITH NAB PACLITAXEL ZHANG
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 PLAN B INDUCTION WITH PACLITAXEL ZHANG
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 PLAN C ZHANG
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 PLAN D ZHANG
- OP RESEARCH PRO00040000 EF 44 LUNAR 2 SCREENING ZHANG
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III ANASTROZOLE ARM 1 PLAN B
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III AT PROGRESSION OF DISEASE
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III EXEMESTANE ARM 1 PLAN C
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III LETROZOLE SOC ARM 1 PLAN A
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III LOW DOSE TAMOXIFEN ARM 2 PLAN E
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III PRIOR TO REGISTRATION
- OP RESEARCH PRO00040327 NAIR A012301 PHASE III TAMOXIFEN ARM 1 PLAN D
- OP RESEARCH PRO00040888 PURI HMCC BR25 001 INITIAL SAFETY LEAD IN FOLLOWED BY PHASE II TRIAL TO STUDY ANTI HCMV THERAPY IN BREAST CANCER PATIENTS ARM 1
- OP RESEARCH PRO00040888 PURI HMCC BR25 001 INITIAL SAFETY LEAD IN FOLLOWED BY PHASE II TRIAL TO STUDY ANTI HCMV THERAPY IN BREAST CANCER PATIENTS SCREENING
- OP RESEARCH PRO00041696 ABDELRAHIM RP2 003 PHASE 2 ARM 2 BILIARY TRACT CANCER COHORT
- OP RESEARCH PRO00041696 ABDELRAHIM RP2 003 PHASE 2 ARM 2 BILIARY TRACT CANCER COHORT SCREENING
- OP RESEARCH PRO00042594 GOG 3119 INDUCTION 1 KAMAT
- OP RESEARCH PRO00042594 GOG 3119 INDUCTION 2 KAMAT
- OP RESEARCH PRO00042594 GOG 3119 MAINTENANCE TREATMENT ARM A KAMAT
- OP RESEARCH PRO00042594 GOG 3119 MAINTENANCE TREATMENT ARM B KAMAT
- OP RESEARCH PRO00042594 GOG 3119 OPTIONAL EXTENDED INDUCTION KAMAT
- OP RESEARCH PRO00042594 GOG 3119 PEMBROLIZUMAB TREATMENT FOR PARTICIPANTS WITHOUT DISEASE PROGRESSION WHO ARE NOT ELIGIBLE FOR MAINTENANCE KAMAT
- OP RESEARCH PRO00042594 GOG 3119 SUBSEQUENT MAINTENANCE TREATMENT ARM A KAMAT
- OP RESEARCH PRO00042594 GOG 3119 SUBSEQUENT MAINTENANCE TREATMENT ARM B KAMAT
- OP RESEARCH PRO0035580 BR22 SCREENING BASELINE
- OP RESEARCH PRO0035580 BR22 TREATMENT
- OP RITUXIMAB WEEKLY X 4
- OP RITUXIMAB 375 EVERY 2 MONTHS MAINTENANCE
- OP RITUXIMAB 375 MG M2 EVERY 21 DAYS
- OP RITUXIMAB 500 MG M2 EVERY 14 DAYS
- OP ROMIDEPSIN
- OP RSH PRO00026304 INFORM STUDY ABDELRAHIM
- OP RSH PRO00036001 CA057 008 ARM A CC 92480 CARFILZOMIB DEXAMETHASONE
- OP RSH PRO00036001 CA057 008 ARM B OPTION 1 CARFILZOMIB DEXAMETHASONE
- OP RSH PRO00036001 CA057 008 ARM B OPTION 2 CARFILZOMIB DEXAMETHASONE
- OP RSH PRO00036001 CA057 008 SCREENING
- OP RSH PRO00036343 IMCGP100 203 ARM C
- OP RSH PRO00037694 ALLIANCE A012103 JAIN ARM 1 Q 42 DAYS
- OP RSH PRO00037694 ALLIANCE A012103 JAIN ARM 1 Q21 DAYS
- OP RSH PRO00037694 ALLIANCE A012103 JAIN ARM 2 OBSERVATION
- OP RSH PRO00037694 ALLIANCE A012103 JAIN SCREENING
- OP RSH PRO00037695 HN009 ARM 1 AND 3
- OP RSH PRO00037695 HN009 ARM 2 AND 4
- OP RSH PRO00037695 HN009 BASELINE SCREENING
- OP RSH PRO00037870 PERIOPERATIVE COHORT ADJUVANT PERIOD
- OP RSH PRO00037870 PERIOPERATIVE COHORT NEOADJUVANT PERIOD
- OP RSH PRO00038020 ZHANG M23 721 SCREENING
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 1 WITH CARBOPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 1 WITH CISPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 2 WITH CARBOPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 2 WITH CISPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 3 WITH CARBOPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 3 WITH CISPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 4 WITH CARBOPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 1 PHASE 2 COHORT 4 WITH CISPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 2 PHASE 3 ARM 1 ARM 2 WITH CISPLATIN
- OP RSH PRO00038020 ZHANG M23 721 STAGE 2 PHASE 3 ARM 1 ARM 2 WITH CARBOPLATIN
- OP RSH PRO00038031 ABDELRAHIM PHASE 1 5FU HT FOLFIRI HT BEVACIZUMAB
- OP RSH PRO00038031 ABDELRAHIM PHASE 1 5FU HT FOLFIRI HT CETUXIMAB
- OP RSH PRO00038031 ABDELRAHIM PHASE 1 5FU HT FOLFOX HT BEVACIZUMAB
- OP RSH PRO00038031 ABDELRAHIM PHASE 1 5FU HT FOLFOX HT CETUXIMAB
- OP RSH PRO00038031 ABDELRAHIM PHASE 1 5FU HT SCREENING
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 ARM 2 TOPOTECAN
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 ARM 2 GEMCITABINE EVERY 21 DAYS
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 ARM 2 IRINOTECAN EVERY 42 DAYS
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 ARM 2 PEMETREXED EVERY 21 DAYS
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 ARM 2 TISOTUMAB VEDOTIN
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 ARM 2 VINORELBINE EVERY 21 DAYS
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 PHASE 3 ARM 1 MK 2870
- OP RSH PRO00038214 RAMIREZ MK 2870 020 GOG 3101 RUN IN SINGLE ARM MK 2870
- OP RSH PRO00038231 ZHANG DS7300 188 IND144591 ARM 1 I DXD
- OP RSH PRO00038231 ZHANG DS7300 188 IND144591 ARM 2 SOC LURBINECTEDIN
- OP RSH PRO00038231 ZHANG DS7300 188 IND144591 ARM 2 SOC TOPOTECAN
- OP RSH PRO00038231 ZHANG DS7300 188 IND144591 SCREENING
- OP RSH PRO00038249 H 55540 AXATILIMAB
- OP RSH PRO00038342 ALE1001 SHAH PHASE 1 and PHASE 2 POST ALLO HSCT MAINTENANCE PHASE
- OP RSH PRO00038351 GOG 3096 PHASE 3 TOPOTECAN 4MG M2 28 DAYS
- OP RSH PRO00038351 GOG 3096 PHASE 3 PLD EVERY 28 DAYS
- OP RSH PRO00038351 GOG 3096 PHASE3 PACLITAXEL EVERY 28 DAYS
- OP RSH PRO00038351 GOG 3096 PHASE 3 TOPOTECAN 1.25MG M2 21 DAYS
- OP RSH PRO00038351 GOG 3096 PHASE 3 R DXD EVERY 21 DAYS
- OP RSH PRO00038360 PINGALI JCAR017 FOL 001 EXTENDED POST TREATMENT FOLLOW UP PERIOD
- OP RSH PRO00038360 PINGALI JCAR017 FOL 001 LEUKAPHERESIS AND PRETREATMENT PERIOD
- OP RSH PRO00038360 PINGALI JCAR017 FOL 001 SCREENING
- OP RSH PRO00038360 PINGALI JCAR017 FOL 001 TREATMENT AND POST TREATMENT PERIOD
- OP RSH PRO00038439 SHAH AC220 168 BIOSAMPLE SCREENING ARM OR PERIOD THAT IS “OPTIONAL”
- OP RSH PRO00039535 MK5909 003 COHORT A 1 ARM 2
- OP RSH PRO00039535 MK5909 003 COHORT B 1
- OP RSH PRO00039797 SUN MK 1022 ADJUVANT ARM B NO PCR WITH PEMBROLIZUMAB AC
- OP RSH PRO00039797 SUN MK 1022 ADJUVANT ARM B NO PCR WITH PEMBROLIZUMAB OLAPARIB
- OP RSH PRO00039797 SUN MK 1022 ADJUVANT PHASE ARM A IF PCR WITH PEMBROLIZUMAB
- OP RSH PRO00039797 SUN MK 1022 ADJUVANT PHASE ARM B NO PCR WITH PEMBROLIZUMAB CAPECITABINE
- OP RSH PRO00039797 SUN MK 1022 NEOADJUVANT PHASE ARM A
- OP RSH PRO00039797 SUN MK 1022 NEOADJUVANT TREATMENT PHASE ARM B
- OP RSH PRO00039797 SUN MK 1022 NEOADJUVANT TREATMENT PHASE ARM C
- OP RSH PRO00039797 SUN MK 1022 SCREENING
- OP RSH PRO00039797 SUN MK 1022 SURGERY PHASE
- OP RSH PRO00039835 EFSTATHIOU MK 2400 001 ARM 1
- OP RSH PRO00039835 EFSTATHIOU MK 2400 001 ARM 2
- OP RSH PRO00039835 EFSTATHIOU MK 2400 001 SCREENING
- OP RSH PRO00040158 PRATH A032201 ARM 1 PLAN A
- OP RSH PRO00040158 PRATH A032201 ARM 1 PLAN B
- OP RSH PRO00040158 PRATH A032201 ARM 2
- OP RSH PRO00040158 PRATH A032201 SCREENING
- OP RSH PRO00041272 ZHANG J3M MC JZQH PLAN 1 ARM A OLOMORASIB PLACEBO PEMBRO
- OP RSH PRO00041272 ZHANG J3M MC JZQH PLAN 1 ARM B OLOMORASIB PLACEBO DURVA
- OP RSH PRO00041272 ZHANG J3M MC JZQH PLAN 2 ARM A ARM B OLOMORASIB PLACEBO MONOTHERAPY MAINTENANCE
- OP RSH PRO00041272 ZHANG J3M MC JZQH PRESCREENING AND SCREENING
- OP RSH PRO00041362 EFSTATHIOU 78278343PCR3001 SCREENING
- OP RSH PRO00041362 EFSTATHIOU 78278343PCR3001 TREATMENT ARM 1
- OP RSH PRO00041430 TRAN NRG GI011 DOSE ESCALATED RT ARM 2 MFOLFIRINOX
- OP RSH PRO00041430 TRAN NRG GI011 DOSE ESCALATED RT ARM 2 NAB PACLITAXEL GEMCITABINEABRAXANE
- OP RSH PRO00041430 TRAN NRG GI011 CHEMOTHERAPY FOR ARM 1 CHEMORADIATION WITH 5 FU
- OP RSH PRO00041430 TRAN NRG GI011 CHEMOTHERAPY FOR ARM 1 CHEMORADIATION WITH CAPECITABINE
- OP RSH PRO00041430 TRAN NRG GI011 CHEMOTHERAPY FOR ARM 1 MFOLFIRINOX
- OP RSH PRO00041430 TRAN NRG GI011 CHEMOTHERAPY FOR ARM 1 NAB PACLITAXEL GEMCITABINE ABRAXANE
- OP RSH PRO00041430 TRAN NRG GI011 CHEMOTHERAPY FOR ARM 1 NALIRIFOX
- OP RSH PRO00041430 TRAN NRG GI011 DOSE ESCALATED RT ARM 2 NALIRIFOX
- OP RSH PRO00041680 ABDELRAHIM HCC 23 116 PHASE 2 COHORT A
- OP RSH PRO00041680 ABDELRAHIM HCC 23 116 PHASE 2 COHORT B
- OP RSH PRO00041680 ABDELRAHIM HCC 23 116 SAFETY LEAD IN
- OP RSH PRO00041680 ABDELRAHIM HCC 23 116 SCREENING
- OP RSH PRO00041722 NIRAVATH RLY 2608 102 ARM 1
- OP RSH PRO00041722 NIRAVATH RLY 2608 102 ARM 2
- OP RSH PRO00041722 NIRAVATH RLY 2608 102 SCREENING
- OP RSH PRO00041872 AT148009 MAI SINGLE ARM ARM A EVORPACEPT TRASTUZUMAB CAPECITABINE
- OP RSH PRO00041872 AT148009 MAI SINGLE ARM ARM B EVORPACEPT TRASTUZUMAB ERIBULIN
- OP RSH PRO00041872 AT148009 MAI SINGLE ARM ARM C EVORPACEPT TRASTUZUMAB GEMCITABINE
- OP RSH PRO00041872 AT148009 MAI SINGLE ARM ARM D EVORPACEPT TRASTUZUMAB PACLITAXEL
- OP RSH PRO00041872 AT148009 MAI SINGLE ARM ARM E EVORPACEPT TRASTUZUMAB VINORELBINE
- OP RSH PRO00041872 AT148009 MAI SINGLE ARM PHASE 2 MULTICENTER STUDY OF EVORPACEPT IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY SCREENING
- OP RSH PRO00042030 ZHANG MK 6070 003 ARM 4 PART B
- OP RSH PRO00042030 ZHANG MK 6070 003 SCREENING RESCREENING
- OP RSH PRO00042047 GUAN C3651021 OPTIONAL OPEN LABEL EXTENSION ARM B PLAN B PONSEGROMAB NAB PACLITAXEL AND GEMCITABINE
- OP RSH PRO00042047 GUAN C3651021 OPTIONAL OPEN LABEL EXTENSION ARM B PLAN B PONSEGROMAB MFOLFIRINOX
- OP RSH PRO00042047 GUAN C3651021 PHASE 2B AND 3 ARM A PLAN A PONSEGROMAB MFOLFIRINOX
- OP RSH PRO00042047 GUAN C3651021 PHASE 2B AND 3 ARM A PLAN A PONSEGROMAB NAB PACLITAXEL AND GEMCITABINE
- OP RSH PRO00042047 GUAN C3651021 PRE RANDOMIZATION SCREENING CHEMOTHERAPY ONLY NAB PACLITAXEL GEMCITABINE
- OP RSH PRO00042047 GUAN C3651021 PRE RANDOMIZATION SCREENING CHEMOTHERAPY ONLY MFOLFIRINOX
- OP RSH PRO00042503 GUAN DS7300 202 ARM EXPERIMENTAL I DXD
- OP RSH PRO00042503 GUAN DS7300 202 ARM INVESTIGATOR’S CHOICE DOCETAXEL
- OP RSH PRO00042503 GUAN DS7300 202 ARM INVESTIGATOR’S CHOICE IRINOTECAN HCL
- OP RSH PRO00042503 GUAN DS7300 202 ARM INVESTIGATOR’S CHOICE PACLITAXEL
- OP RSH PRO00042503 GUAN DS7300 202 SCREENING
- OP RSH PRO00042841 PRATH CCTG PR26 DOCETAXEL STANDARD ADT ARPI ARM 2
- OP RSH PRO00042841 PRATH CCTG PR26 STANDARD ADT ARPI ARM 1
- OP RSH PRO00042841 PRATH CCTG PR26 SCREENING
- OP SACITUZUMAB GOVITECAN D1D8 EVERY 21 DAYS
- OP SALTZ
- OP SIMPLIFIED INFUSIONAL FLUOROURACIL LEUCOVORIN EVERY 14 DAYS
- OP SIPULEUCEL T PROVENGE EVERY 14 DAYS
- OP SUBCUTANEOUS PERTUZUMAB TRASTUZUMAB HYALURONIDASE EVERY 21 DAYS
- OP TAFASITAMAB CXIX
- OP TC
- OP TECLISTAMAB CQYV MAINTENANCE
- OP TEMSIROLIMUS WEEKLY
- OP TISOTUMAB VEDOTIN TFTV EVERY 21 DAYS
- OP TOPOTECAN WEEKLY
- OP TOPOTECAN BEVACIZUMAB
- OP TOPOTECAN BEVACIZUMAB EVERY 28 DAYS
- OP TOPOTECAN D1 D5 EVERY 21 DAYS
- OP TORIPALIMAB
- OP TRABECTEDIN 24 HR AMBULATORY PUMP EVERY 21 DAYS
- OP TRABECTEDIN NO AMBULATORY PUMP EVERY 21 DAYS
- OP TRANSARTERIAL CHEMOEMBOLIZATION
- OP TRASTUZUMAB EVERY 21 DAYS PACLITAXEL EVERY 7 DAYS
- OP TRASTUZUMAB LOADING AND MAINTENANCE CAPECITABINE EVERY 21 DAYS
- OP TRASTUZUMAB PACLITAXEL EVERY 7 DAYS
- OP TRASTUZUMAB PERTUZUMAB EVERY 21 DAYS LOADING AND MAINTENANCE DOSE
- OP TRASTUZUMAB PERTUZUMAB DOCETAXEL EVERY 21 DAYS
- OP TRASTUZUMAB PERTUZUMAB DOCETAXEL CARBOPLATIN LOADING AND MAINTENANCE REGIMEN
- OP TRASTUZUMAB PERTUZUMAB WEEKLY PACLITAXEL EVERY 21 DAYS
- OP TRASTUZUMAB AND HYALURONIDASE EVERY 21 DAYS MAINTENANCE
- OP TRASTUZUMAB LOADING AND MAINTENANCE DOSE EVERY 21 DAYS
- OP TREMELIMUMAB ONCE DURVALUMAB EVERY 28 DAYS
- OP TVEC
- OP VDC
- OP VINCRISTINE
- OP VINORELBINE D1D8 EVERY 21 DAYS
- OP VIP
- OP WEEKLY CARBOPLATIN AUC 1.5 WEEKLY PACLITAXEL PEMBROLIZUMAB EVERY 21 DAYS
- OP WEEKLY ELOTUZUMAB EVERY 28 DAYS
- OP WEEKLY NAB PACLITAXEL D1D8D15 EVERY 28 DAYS
- OP XELIRI PANITUMUMAB EVERY 7 DAYS
- OP XELOX BEVACIZUMAB EVERY 21 DAYS
- OP ZOLBETUXIMAB CAPOX CAPECITABINE AND OXALIPLATIN
- OP ZOLBETUXIMAB MFOLFOX6 FLUOROURACIL LEUCOVORIN OXALIPLATIN
- OP IP CAGT CYCLOPHOSPHAMIDE FLUDARABINE BREXUCABTAGENE AUTOLEUCEL
- OP IP CAGT CYCLOPHOSPHAMIDE FLUDARABINE CILTACABTAGENE AUTOLEUCEL
- OP IP CAGT CYCLOPHOSPHAMIDE FLUDARABINE IDECABTAGENE VICLEUCEL
- OP IP CAGT CYCLOPHOSPHAMIDE FLUDARABINE LISOCABTAGENE MARALEUCEL
- OP IP CAGT CYCLOPHOSPHAMIDE FLUDARABINE OBECABTAGENE AUTOLEUCEL HIGH TUMOR BURDEN DOSAGE REGIMEN
- OP IP CAGT CYCLOPHOSPHAMIDE FLUDARABINE OBECABTAGENE AUTOLEUCEL LOW TUMOR BURDEN DOSAGE REGIMEN
- OP IP EP EMA
- OP IP EPCORITAMAB BYSP
- OP IP RESEARCH CTL H 43516 CARMEN
- OP IP RESEARCH PRO00038339 YUEN S2213 PHASE III RANDOMIZED STUDY OF DARA VCD FOR NEW AL AMYLOIDOSIS CONSOLIDATION ARM 2
- OP IP RESEARCH PRO00038753 LIAO
- OP IP RESEARCH PRO00040227 CYTB323I12201 KAZZAZ PHASE 2 OPEN LABEL RAPCABTAGENE AUTOLEUCEL VERSION COMPARATOR FOR GPA OR MPA
- OP IP RSH PRO00039683 YUEN PART A COHORT 1
- OP IP RSH PRO00039683 YUEN PART A COHORT 2
- OP IP RSH PRO00039683 YUEN PART B
- OPDIVO QVANTIG NIVOLUMAB HYALURONIDASE NVHY 14 DAY CYCLES MONOTHERAPY
- OPDIVO QVANTIG NIVOLUMAB HYALURONIDASE NVHY 21 DAY CYCLES MONOTHERAPY
- OPDIVO QVANTIG NIVOLUMAB HYALURONIDASE NVHY 28 DAY CYCLES MONOTHERAPY
- PRO00039821 AC220 167 ARM 1
- PRO00039821 AC220 167 ARM 2
- PRO00039821 AC220 167 BASELINE SCREENING
- PRO00039821 AC220 167 SUB STUDY
- RESEARCH HILL CTL H 43761 CRIMSON NE
- RESEARCH HILL CTL H 43761 CRIMSON NE FOLLOW UP
- RESEARCH HILL CTL H 43761 CRIMSON NE PROCUREMENT ORDERS
- RESEARCH CTL GENERIC BLOOD COLLECTION ORDERS
- RESEARCH CTL GENERIC INFUSION ORDERS
- RESEARCH CTL H 23574 CHARKALL FOLLOW UP LABS OP
- RESEARCH CTL H 35626 LULLA TACTAM
- RESEARCH CTL H 37966 RELY 30
- RESEARCH CTL H 37966 RELY 30 FOLLOW UP LABS OP
- RESEARCH CTL H 37966 RELY 30 INITIAL PROCUREMENT ORDERS
- RESEARCH CTL H 40466 MAGENTA
- RESEARCH CTL H 40466 MAGENTA FOLLOW UP LABS OP
- RESEARCH CTL H 44526 ANCHOR
- RESEARCH CTL H 46604 BESTA DONOR PROCUREMENT
- RESEARCH FT522 H 53764 REGIMEN B
- RESEARCH H 45118 DONOR PROCUREMENT FOR THIRD PARTY MULTIVIRUS SPECIFIC T CELL LINES
- RESEARCH LULLA GLYCAR H 38942
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A PEGYLATED LIPOSOMAL DOXORUBICIN 40 VERSION 9 08 22 2016
- RESEARCH PRO00012803 GOG0281 KAMAT ARM A PEGYLATED LIPOSOMAL DOXORUBICIN 50 VERSION 9 08 22 2016
- RESEARCH PRO00019188 RANDHAWA CALB001A2301
- RESEARCH PRO00020138 CHANG ESR 17 13153
- RESEARCH PRO00020925 ABDELRAHIM ASTELLAS PH3 GLOW
- RESEARCH PRO00022968 KAMAT NRG GY018
- RSH IP OP PRO00036433 SGN70 101 TREATMENT
- RSH OP PRO00036433 SGN70 101 SCREENING BASELINE
- RSH OP PRO00037396 NRG GY026 ARM 1
- RSH OP PRO00037396 NRG GY026 ARM 2
- RSH OP PRO00037396 NRG GY026 ARM 3
- RSH OP PRO00037917 BR23 001 ARM 1
- RSH OP PRO00037917 BR23 001 ARM 2
- RSH OP PRO00037917 BR23 001 SCREENING
- RSH PRO00036343 IMCGP100 203 BASELINE SCREENING
- Therapy_Plan_DONANEMAB (KISUNLA) STANDARD DOSING INFUSION
- Therapy_Plan_PEMIVIBART (PEMGARDA)
- Therapy_Plan_TOFERSEN (QALSODY) INTRATHECAL INJECTION
- Therapy_Plan_TOCILIZUMAB (CABMR) INFUSION
- Therapy_Plan_CAGT- POST AUTOLOGOUS STEM CELL TRANSPLANT IMMUNIZATIONS
- Therapy_Plan_LASIX/BUMEX THERAPY PLAN
- Therapy_Plan_LEUPROLIDE DEPOT (LUPRON) Q12WEEKS
- Therapy_Plan_BMT CERT EMERGENCY ORDERS
- Therapy_Plan_VYVGART HYTRULO WEEKLY SQ FOR CIDP
- Therapy_Plan_CYTOMEGALOVIRUS IMMUNE GLOBULIN 100-150 MG/KG FOR PANCREAS TRANSPLANT
- Therapy_Plan_CAGT- POST ALLOGENEIC STEM CELL TRANSPLANT IMMUNIZATIONS
- Therapy_Plan_UPLIZNA THERAPY PLAN
- Therapy_Plan_LEQEMBI 10 MG/KG INFUSION
- Therapy_Plan_HEMATOLOGY LAB THERAPY PLAN
- Therapy_Plan_ZOLEDRONIC ACID (ZOMETA) INFUSION EVERY 6 MONTHS
- Therapy_Plan_AXATILIMAB (NIKTIMVOTM) INFUSION
- Therapy_Plan_RISANKIZUMAB-RZAA (SKYRIZI) LOADING DOSE INFUSION FOR ULCERATIVE COLITIS
- Therapy_Plan_SALINE SUPPRESSION TEST FOR HYPERALDOSTERONISM
- Therapy_Plan_SECUKINUMAB (COSENTYX) INFUSION
- Therapy_Plan_ADAMTS13 (ADZYNMA) WEEKLY INFUSION
- Therapy_Plan_FULVESTRANT
- Therapy_Plan_MONOFERRIC INFUSION
- Therapy_Plan_BEZLOTOXUMAB (ZINPLAVA) INFUSION
- Therapy_Plan_FERRIC CARBOXYMALTOSE (INJECTAFER) 15 MG/KG INFUSION
- Therapy_Plan_FERUMOXYTOL (FERAHEME) 1020 MG INFUSION
- Therapy_Plan_THYMOGLOBULIN FOR KIDNEY TRANSPLANT REJECTION
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) ONCE
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) 500 MG
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) 375 MG/M2 – NEUROLOGY/RHEUMATOLOGY
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) 375 MG/M2
- Therapy_Plan_RITUXIMAB 1000 MG FOR RHEUMATOLOGY
- Therapy_Plan_ETESEVIMAB-BAMLANIVIMAB INFUSION
- Therapy_Plan_CARFILZOMIB (KYPROLIS) FOR AMR
- Therapy_Plan_RESEARCH PRO00024239 / GABER ISATUXIMAB INFUSION
- Therapy_Plan_ROMOSOZUMAB (EVENITY) SQ EVERY 4 WEEKS
- Therapy_Plan_BENRALIZUMAB (FASENRA) SQ EVERY 8 WEEKS (MAINTENANCE)
- Therapy_Plan_BENRALIZUMAB (FASENRA) SQ EVERY 4 WEEKS
- Therapy_Plan_DONANEMAB (KISUNLA) TITRATED DOSING INFUSION
- Therapy_Plan_ARANESP (DARBEPOETIN) FOR CKD
- Therapy_Plan_TOCILIZUMAB-AAZG (TYENNE) INFUSION FOR RHEUMATOLOGY
- Therapy_Plan_RESEARCH PRO00037880 INFUSION TREATMENT / HUANG
- Therapy_Plan_ROZANOLIXIZUMAB (RYSTIGGO) INFUSION
- Therapy_Plan_LONG 10-HOUR IOHEXOL (OMNIPAQUE) CLEARANCE FOR MEASURING GFR
- Therapy_Plan_VUTRISIRAN (AMVUTTRA) SUBCUTANEOUS INJECTION
- Therapy_Plan_DESMOPRESSIN STIMULATION TEST
- Therapy_Plan_GLUCAGON STIMULATION TEST
- Therapy_Plan_INCLISIRAN (LEQVIO) SUBCUTANEOUS INJECTION
- Therapy_Plan_GROWTH HORMONE SUPPRESION TEST
- Therapy_Plan_RISANKIZUMAB-RZAA (SKYRIZI) INFUSION
- Therapy_Plan_DEGARELIX SUBCUTANEOUS INJECTION (LOADING & MAINTENANCE)
- Therapy_Plan_DEGARELIX SUBCUTANEOUS INJECTION (LOADING DOSE ONLY)
- Therapy_Plan_BEVACIZUMAB INFUSION EVERY 21 DAYS
- Therapy_Plan_VEDOLIZUMAB (ENTYVIO) INFUSION – LOADING DOSE ONLY
- Therapy_Plan_EFGARTIGIMOD ALFA INFUSION (VYVGART) OR EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC SQ INJECTION (VYVGART HYTRULO)
- Therapy_Plan_RITUXIMAB-ABBS (TRUXIMA) – SM 1101
- Therapy_Plan_ORITAVANCIN (KIMYRSA) INFUSION
- Therapy_Plan_INFLIXIMAB-AXXQ (AVSOLA) MAINTENANCE INFUSION
- Therapy_Plan_INFLIXIMAB-AXXQ (AVSOLA) INFUSION
- Therapy_Plan_AVALGLUCOSIDASE ALFA-NGPT INFUSION
- Therapy_Plan_ANIFROLUMAB (SAPHNELO) INFUSION
- Therapy_Plan_RETACRIT (EPOETIN ALFA-EPBX)
- Therapy_Plan_DESMOPRESSIN 0.3 MCG/KG INFUSION FOR STIMULATION TEST (MAX DOSE 20 MCG)
- Therapy_Plan_OUTPATIENT ELECTROLYTE REPLACEMENT
- Therapy_Plan_EPTINEZUMAB (VYEPTI) INFUSION
- Therapy_Plan_RITUXAN-PVVR (RUXIENCE) – SMITH 1101
- Therapy_Plan_TEPROTUMUMAB INFUSION
- Therapy_Plan_ORITAVANCIN (ORBACTIV) INFUSION
- Therapy_Plan_LUSPATERCEPT (REBLOZYL) INJECTION EVERY 3 WEEKS
- Therapy_Plan_INFLIXIMAB-DYYB (INFLECTRA) INFUSION
- Therapy_Plan_CRIZANLIZUMAB (ADAKVEO) INFUSION
- Therapy_Plan_ULTOMIRIS FOR PNH (RAVULIZUMAB-CWVZ)
- Therapy_Plan_RITUXIMAB (RITUXAN) – SMITH 1101 RHEUMATOLOGY
- Therapy_Plan_STANDARD 4-HOUR IOHEXOL (OMNIPAQUE) CLEARANCE FOR MEASURING GFR
- Therapy_Plan_USTEKINUMAB (STELARA) SUBCUTANENOUS INJECTION FOR CROHN DISEASE (MAINTENANCE)
- Therapy_Plan_PATISIRAN (ONPATTRO) INFUSION
- Therapy_Plan_USTEKINUMAB (STELARA) SUBCUTANEOUS INJECTION FOR PSORIASIS
- Therapy_Plan_NUSINERSEN (SPINRAZA) FOR SPINAL MUSCULAR ATROPHY (SMA) MAINTENANCE DOSE
- Therapy_Plan_NUSINERSEN (SPINRAZA) FOR SPINAL MUSCULAR ATROPHY (SMA) LOADING DOSE
- Therapy_Plan_OCRELIZUMAB (OCREVUS) INFUSION
- Therapy_Plan_NATALIZUMAB INFUSION EVERY 4 WEEKS
- Therapy_Plan_ACUTE HYPERSENSITIVITY GUIDELINES
- Therapy_Plan_LEUPROLIDE (LUPRON DEPOT) IM INJECTION – FEMALE
- Therapy_Plan_INTRAVENOUS ANTIBIOTICS THERAPY PLAN
- Therapy_Plan_NEUROLOGY ONLY – MIGRAINE INFUSIONS
- Therapy_Plan_RESEARCH SCREENING PRO0009707 MTG-REIC-PC003 MILES
- Therapy_Plan_BLOOD & PLATELET TRANSFUSION
- Therapy_Plan_EPOETIN ALFA (PROCRIT) INJECTION ONCOLOGY
- Therapy_Plan_DENOSUMAB (PROLIA) INJECTION
- Therapy_Plan_PAMIDRONATE (AREDIA) INFUSION
- Therapy_Plan_FERUMOXYTOL (FERAHEME) 510 MG INFUSION
- Therapy_Plan_FERRIC CARBOXYMALTOSE (INJECTAFER) 750 MG INFUSION
- Therapy_Plan_PEGLOTICASE (KRYSTEXXA) INFUSION
- Therapy_Plan_CERTOLIZUMAB PEGOL (CIMZIA) INJECTION 400 MG
- Therapy_Plan_ZOLEDRONIC ACID (RECLAST) INFUSION
- Therapy_Plan_GOLIMUMAB (SIMPONI ARIA) INFUSION
- Therapy_Plan_ABATACEPT (ORENCIA) INFUSION
- Therapy_Plan_SOLUMEDROL BOOSTER MONTHLY 1000 MG (METHYLPREDNISOLONE)
- Therapy_Plan_SOLUMEDROL BOOSTER WEEKLY 1000 MG (METHYLPREDNISOLONE)
- Therapy_Plan_SOLUMEDROL INDUCTION 1250 MG (METHYLPREDNISOLONE)
- Therapy_Plan_SOLUMEDROL INDUCTION 1000 MG (METHYLPREDNISOLONE)
- Therapy_Plan_IVIG INFUSION 0.5 GM/KG FOR LUNG TRANSPLANT
- Therapy_Plan_IVIG INFUSION 1 GM/KG FOR LUNG TRANSPLANT
- Therapy_Plan_INFLIXIMAB INFUSION
- Therapy_Plan_BELIMUMAB (BENLYSTA) INFUSION
- Therapy_Plan_IVIG INDUCTION INFUSION 0.6 GM/KG DAILY X4
- Therapy_Plan_IVIG INDUCTION INFUSION 0.4 GM/KG DAILY X5
- Therapy_Plan_LEUPROLIDE (ELIGARD) SQ INJECTION
- Therapy_Plan_BASILIXIMAB (SIMULECT) INFUSION
- Therapy_Plan_USTEKINUMAB (STELARA) INDUCTION INFUSION
- Therapy_Plan_RHO(D) IMMUNE GLOBULIN (RHOGAM) INJECTION
- Therapy_Plan_STEM CELL / DONOR LYMPHOCYTE COLLECTION
- Therapy_Plan_THERAPEUTIC APHERESIS – WBC REDUCTION
- Therapy_Plan_THERAPEUTIC APHERESIS – THERAPEUTIC PLASMA EXCHANGE
- Therapy_Plan_THERAPEUTIC APHERESIS – RBC EXCHANGE
- Therapy_Plan_THERAPEUTIC APHERESIS – PLATELET REDUCTION
- Therapy_Plan_THERAPEUTIC APHERESIS – LDL APHERESIS
- Therapy_Plan_GILENYA (FINGOLIMOD) FIRST DOSE PROTOCOL (DR. SIMPSON)
- Therapy_Plan_COSYNTROPIN (CORTROSYN) INJECTION
- Therapy_Plan_IVIG BOOSTER INFUSION (ST. JOHNS – DEFAULT PT SUPPLIED)
- Therapy_Plan_POST SPLENECTOMY IMMUNIZATIONS
- Therapy_Plan_CIDOFOVIR (VISTIDE) INFUSION FOR CMV
- Therapy_Plan_CYTOMEGALOVIRUS IMMUNE GLOBULIN (CYTOGAM) INFUSION
- Therapy_Plan_WINRHO SDF INJECTION
- Therapy_Plan_MORPHINE INTRATHECAL INJECTION TRIAL
- Therapy_Plan_SILTUXIMAB (SYLVANT) INFUSION
- Therapy_Plan_CIDOFOVIR (VISTIDE) INFUSION FOR KIDNEY TRANSPLANT
- Therapy_Plan_MICAFUNGIN (MYCAMINE) INFUSION
- Therapy_Plan_CAGT- PALIFERMIN (KEPIVANCE) INJECTION
- Therapy_Plan_CYCLOPHOSPHAMIDE (CYTOXAN) INFUSION ONCE
- Therapy_Plan_SOLUMEDROL INDUCTION 500 MG (METHYLPREDNISOLONE)
- Therapy_Plan_IVIG INFUSION 1 GM/KG FOR KIDNEY TRANSPLANT
- Therapy_Plan_METHOTREXATE IM INJECTION (ONCE)
- Therapy_Plan_IVIG BOOSTER (MULTI-DAY) INFUSION
- Therapy_Plan_INFLIXIMAB MAINTENANCE INFUSION
- Therapy_Plan_EPOETIN ALFA (PROCRIT) INJECTION NON-ONCOLOGY
- Therapy_Plan_BLOOD TRANSFUSION
- Therapy_Plan_PLATELET TRANSFUSION
- Therapy_Plan_FRESH FROZEN PLASMA TRANSFUSION
- Therapy_Plan_CRYOPRECIPITATE TRANSFUSION
- Therapy_Plan_PENTAMIDINE (PENTAM) INFUSION
- Therapy_Plan_THERAPEUTIC PHLEBOTOMY
- Therapy_Plan_BACLOFEN (LIORESAL) INTRATHECAL INJECTION TRIAL
- Therapy_Plan_DEFEROXAMINE (DESFERAL) INFUSION
- Therapy_Plan_CENTRAL VENOUS CATHETER MAINTENANCE
- Therapy_Plan_DEXAMETHASONE (DECADRON) INFUSION
- Therapy_Plan_PEGFILGRASTIM-JMDB (FULPHILA) SQ INJECTION
- Therapy_Plan_LANREOTIDE (SOMATULINE DEPOT) SQ INJECTION
- Therapy_Plan_OCTREOTIDE DEPOT (SANDOSTATIN LAR) IM INJECTION
- Therapy_Plan_FILGRASTIM (ZARXIO) SQ INJECTION
- Therapy_Plan_FILGRASTIM (NEUPOGEN) SQ INJECTION
- Therapy_Plan_ROMIPLOSTIM (NPLATE) SQ INJECTION
- Therapy_Plan_SOLIRIS FOR PNH (ECULIZUMAB)
- Therapy_Plan_LEUPROLIDE (LUPRON DEPOT) IM INJECTION – MALE
- Therapy_Plan_GOSERELIN (ZOLADEX) SQ INJECTION
- Therapy_Plan_VITAMIN B12 (CYANOCOBALAMIN) INJECTION
- Therapy_Plan_BELATACEPT (NULOJIX) MAINTENANCE INFUSION
- Therapy_Plan_CEREZYME (IMIGLUCERASE) INFUSION
- Therapy_Plan_BLANK THERAPY PLAN
- Therapy_Plan_IRON SUCROSE COMPLEX (VENOFER) INFUSION
- Therapy_Plan_ZOLEDRONIC ACID (ZOMETA) INFUSION
- Therapy_Plan_DENOSUMAB (XGEVA) INJECTION
- Therapy_Plan_INTRAVENOUS FLUID (IV) INFUSION
- Therapy_Plan_ARANESP (DARBEPOETIN)
- Therapy_Plan_CYCLOPHOSPHAMIDE (CYTOXAN) INFUSION
- Therapy_Plan_FERRIC GLUCONATE (FERRLECIT) INFUSION
- Therapy_Plan_PENTAMIDINE (NEBUPENT) INHALATION
- Therapy_Plan_SOLIRIS FOR AHUS (ECULIZUMAB)
- Therapy_Plan_VEDOLIZUMAB (ENTYVIO) INFUSION
- Therapy_Plan_IRON DEXTRAN COMPLEX (INFED) INFUSION
- Therapy_Plan_VALPROATE SODIUM (DEPACON) INFUSION
- Therapy_Plan_HEPATITIS B IMMUNE GLOBULIN (HBIG) INFUSION
- Therapy_Plan_IVIG BOOSTER INFUSION
- Therapy_Plan_TRANSIENT HEMODIALYSIS THERAPY PLAN
- Therapy_Plan_HEMODIALYSIS THERAPY PLAN
- Therapy_Plan_IVIG INFUSION 0.5 GM/KG FOR KIDNEY TRANSPLANT (MAX 70 GRAMS)
- Therapy_Plan_CAGT- PRE-TRANSPLANT WORKUP
- Therapy_Plan_CAGT- MOZOBIL STEM CELL MOBILIZATION
- Therapy_Plan_CAGT- STEM CELL MONITORING (DEFAULT PT SUPPLIED)
- Therapy_Plan_CAGT- NEUPOGEN STEM CELL MOBILIZATION (DEFAULT PT SUPPLIED)
- Therapy_Plan_CAGT- POST TRANSPLANT IMMUNIZATIONS
- Therapy_Plan_CAGT- DONOR EVALUATION (NMDP/SIBLING)
- Therapy_Plan_CAGT- FEMORAL LINE PLACEMENT W SCC (DONOR CENTER)
- Therapy_Plan_CAGT- DONOR LEUKOCYTE INFUSION (DLI)
- Therapy_Plan_CAGT- COMMON ORDERS
- Therapy_Plan_CAGT- CLINIC PROCEDURE W CONSCIOUS SEDATION
- Therapy_Plan_CAGT- AUTO DAILY ORDERS
- Therapy_Plan_CAGT- ALLO DAILY ORDERS
- Therapy_Plan_CAGT- INTRAVENOUS FLUID (IV)
- Therapy_Plan_CAGT- ECULIZUMAB (SOLIRIS) FOR PNH
- Therapy_Plan_CAGT- IVIG INFUSION
- Therapy_Plan_CAGT- ZOLEDRONIC ACID (ZOMETA) INFUSION
- Therapy_Plan_CAGT- BORTEZOMIB (VELCADE) INJECTION
- Therapy_Plan_CAGT- ECULIZUMAB (SOLIRIS) FOR AHUS
- Therapy_Plan_HM BARIATRIC INFUSION
- Therapy_Plan_THERAPEUTIC APHERESIS – PHOTOPHERESIS
v2.1